Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated

Oncology (Williston Park). 2019 Jul 15;33(7):629388.
No abstract available

MeSH terms

  • BRCA1 Protein / genetics*
  • BRCA2 Protein / genetics*
  • Drug Approval*
  • Female
  • Humans
  • Mutation*
  • Ovarian Neoplasms / drug therapy*
  • Phthalazines / therapeutic use*
  • Piperazines / therapeutic use*
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Progression-Free Survival
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • olaparib